related documents
- OC4. Number and sites of bone lesions and history of skeletal-related events (SREs): Do these parameters correspond with skeletal morbidity and mortality in patients with bone metastases (mets) from hormone-refractory prostate cancer (HRPC)? Conferences
- P79. N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo Conferences
- P81. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover Conferences